BioCryst Pharmaceuticals, Inc.

Good morning and welcome to the BioCHRIST first quarter 2024 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to John Bluth at Biochrist. Please go ahead.

Thanks, Drew. Good morning, and welcome to Biochrist's first quarter 2024 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, and Chief R&D Officer Dr. Helen Thackeray. Following our remarks, we will answer your questions. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP pro forma financial measures. For reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the press releases section of our investor relations website at www.biocrist.com. I'd now like to turn the call over to John Stonehouse.

Thanks, John. We are off to a fantastic start to the year with growing Orladeo revenue and our pipeline advancing on schedule. Orladeo revenue in Q1 exceeded our expectations as the commercial team in the U.S. did a great job successfully navigating the reauthorization process faster than previous years. Charlie will share more detail, but now, in the fourth year since approval, the steady and consistent growth of new patients shows no signs of letting up, and we are even more confident we are on track to reach our goal of $1 billion in global revenue at peak. We continue to make great progress with our prioritized pipeline too. Our Orla Dale pediatric program is on schedule to file for approval next year. We continue to make progress with BCX 10013 and expect we will be able to decide on whether to partner or discontinue the program later this year. In addition, our other pipeline programs, including BCX17725 for Netherton's and Avoralstat for DME, are advancing toward the clinic with first or best-in-class profiles. Over the next 12 months, Orladeo will be approaching the midway point of our global peak revenue goals. We'll be preparing to file for approval for Orladeo use in pediatric patients and we'll be starting to move multiple pipeline programs into patient studies. And last but not least, we will be approaching profitability. The year is off to a strong start with exceptional progress in all these areas, and we are focused on continuing this momentum throughout the year. With that, I'll turn it over to Charlie to share the outstanding performance of Orlodeo for the quarter.